ASCO 2022 | Improving outcomes in Hodgkin lymphoma
Stephen Ansell
• 4 Jun 2022
Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses unmet needs in the field of Hodgkin lymphoma (HL), including increasing rates of complete remission. As patients with HL tend to be younger, long-term remission with first-line therapies and minimal adverse events (AEs) is the ideal goal. Strategies such as using PD-1 inhibitors as well as reducing the amount of treatment will potentially optimize patient outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
